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abstRact
IntroductIon: Extensive weight loss has been docu­
mented in intensive care unit (ICU) survivors, primarily as 
the result of muscle loss, leading to impaired physical func­
tion and reduced quality of life. The aim of the EAT­ICU trial 
is to test the effect of early goal­directed protein­energy 
nutrition based on measured requirements on short­term 
clinical outcomes and long­term physical quality of life in 
ICU patients.
Methods: The EAT­ICU trial is a single­centre, randomised, 
parallel­group trial with concealed allocation and blinded 
outcome assessment. A total of 200 consecutive, acutely 
admitted, mechanically ventilated intensive care patients 
will be randomised 1:1 to early goal­directed nutrition ver­
sus standard of care to show a potential 15% relative risk 
reduction in the primary outcome measure (physical func­
tion) at six months (two­sided significance level α = 0.05; 
power β = 80%). Secondary outcomes include energy­ and 
protein balances, metabolic control, new organ failure, use 
of life support, nosocomial infections, ICU­ and hospital 
length of stay, mortality and cost analyses. 
concLusIon: The optimal nutrition strategy for ICU pa­
tients remains unsettled. The EAT­ICU trial will provide im­
portant data on the effects of early goal­directed protein­
energy nutrition based on measured requirements in these 
patients. 
FundInG: The EAT­ICU trial is funded by Copenhagen Uni­
versity Hospital, Rigshospitalet and Fresenius Kabi A/S and 
supported by The European Society for Clinical Nutrition 
and Metabolism (ESPEN).
trIaL reGIstratIon: Clinicaltrials.gov identifier no. 
NCT01372176.
Advances in the treatment of intensive care patients 
have resulted in a reduction in overall mortality after 
critical illness. A significant part of these surviving pa­
tients experience impaired physical function, which re­
duces their quality of life in the years after discharge  
[1­3]. Studies have documented average weight losses 
of 20% in survivors of long­term admission at the inten­
sive care unit (ICU), primarily as a result of extensive 
muscle loss [3­5]. Patients indicate loss of muscle mass 
as the primary cause of impaired function and reduced 
quality of life [1, 3, 6]. The synergetic effect of immobil­
isation, medicines and inflammatory stress on muscle 
atrophy may be further enhanced by insufficient provi­
sion of nutrients during intensive care. Still, the role of 
nutrition is less investigated.
Recent randomised trials have focused mainly on 
route of nutrition support, timing and whether to pro­
vide patients with a hypo­ or eucaloric nutritional ther­
apy [7­10]. Results are diverging, probably as a result of 
different feeding protocols, difference in case­mix and 
mortality rates. Common to all the trials, though, was 
less attention to the provision of protein.   
Presently, it remains unclear whether supplementary 
parenteral nutrition (PN) should be used for ICU patients 
when nutritional targets are not met with enteral nutri­
tion (EN). Supplementing EN with PN based on indirect 
calorimetry in the early course of ICU admission improved 
clinical outcome (survival and infections) in two rando­
mised trials [7, 9]. In contrast, another large study found 
increased rates of complications with early supplemen­
tary PN in ICU patients [8], however, in this trial indirect 
calorimetry was not employed. In none of the trials nitro­
gen balances were measured, and protein/amino acids 
were provided in doses below those suggested in recent 
observational studies [11, 12]. Adequate amounts of  
protein might accelerate recovery. Based on current re­
search,  randomised trial focussing on providing adequate 
amounts of protein in conjunction with combined EN and 
PN based on indirect calorimetry early in the admission is 
needed to fill the knowledge gap [13]. 
Therefore, in the present study, patients will be ran­
domised to either standard nutritional therapy or early 
goal­directed nutrition. The early goal­directed nutrition 
therapy focuses on both energy and protein, including 
measured requirements (indirect calorimetry and nitro­
gen balance) and early initiation of supplementary PN to 
meet 100% of requirements from day 1 after randomisa­
tion. 
aim
The aim of the EAT­ICU trial is to investigate the effect of 
early goal­directed nutrition versus standard nutritional 
therapy during intensive care on short­term clinical out­
come and long­term quality of life, including physical 
function.
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hypothesis
Early goal­directed protein­energy nutrition provided on 
the basis of measured requirements will improve short­
term clinical outcome as well as long­term quality of life.
mEthOds
This single­centre trial is conducted at the Department 
of Intensive Care, Rigshospitalet, Denmark, using a com­
puter­generated allocation sequence, concealed alloca­
tion and blinded outcome assessment of patients. Pa­
tients are randomised 1:1 to control or intervention 
groups, stratified for the presence of haematological 
malignancy as mortality is markedly higher in this group 
than in other intensive care patients (70% at 90 days in 
the 6S trial [14]). Patients will be screened and included 
according to the criteria presented in table 1. Please see 
Figure 1 for a flow diagram of the trial.
Randomisation
Two computer­generated lists for randomisation, with 
variable block size, have been prepared by a person who 
does not otherwise participate in the trial. Investigators 
draw sequentially numbered, opaque, sealed envelopes 
(in accordance with the SNOSE principles [15]) from one 
of two boxes in a consecutive order depending on the 
presence or absence of haematological malignancy. 
blinding
The allocated nutrition strategy is not masked for re­
search­ and clinical staff caring for the patient. Investiga­
tors assessing rates of nosocomial infections and quality 
of life at six months are masked to the intervention.
Primary outcome measure
– Physical function six months after randomisation 
assessed as physical component summary (PCS) score 
of the short form (SF)­36 v. 1.0 obtained by phone­
interview by a person blinded to the intervention.  
For details on the SF­36 questionnaire, please go to 
www.sf­36.org.
secondary outcome measures
Clarification: Life support outcomes will be analysed as 
percent of days alive without the use of life support in the 
90­day period, in order to reduce the risk of survival bias.
– Accumulated energy­ and protein balance
– New organ failure in the ICU (Y/N) (defined as a 
sepsis­related organ failure assessment (SOFA) score 
of 3 or above in any of the categories [16], excluding 
Glasgow Coma Scale Score) in patients who did not 
have the particular organ failure at randomisation
– Metabolic control: Accumulated insulin administra­
tion to maintain blood glucose ≤ 10 mmol/l and rates 
of severe hyper­ and hypoglycaemia (blood glucose  
> 15 mmol/l and ≤ 2.2 mmol/l, respectively)
– Rate of nosocomial infections (Y/N, yes if positive in 
one of six specific types of infections) [17]
– New onset of renal replacement therapy (Y/N)
– Percent of days alive without renal replacement 
therapy at day 90
abbREviatiOns
6S = Scandinavian Starch for Severe Sepsis/Septic Shock Trial 
CRRT = continuous renal replacement therapy
EN = enteral nutrition
ESPEN = The European Society for Clinical Nutrition and Metabolism
GCP = good clinical practice
ICU = intensive care unit
PCS score = physical component summary score
PN = parenteral nutrition
SAR = serious adverse reaction
SF­36 = short form quality of life questionnaire
SNOSE = sequentially numbered, opaque, sealed envelopes
SOFA score = sepsis­related organ failure assessment score
SUSAR = serious unexpected adverse reactions
tablE 1
Inclusion­ and exclusion criteria for the Early Goal­Directed Nutrition in 
ICU Patients Trial.
Inclusion criteria 
Patients are randomised, included and dosed no later than  
24 h after admission to the ICU
The following criteria must be met to be eligible for inclusion:
Age ≥ 18 yrs
Acutely admitted to the ICU
Expected length of stay in ICU > 3 days 
Mechanically ventilated, which enables indirect calorimetry
Have a central venous catheter wherein parenteral nutrition  
can be administered
Proxy consent obtained  
The ability to read and understand Danish
Exclusion criteria
Contraindications to use enteral nutrition as judged by the clinicians 
Contraindications to use parenteral nutrition, e.g. hypersensitivity  
towards fish­, egg­ or peanut protein, or any of the active substances 
in the PN products
Receiving a special diet
Burn injury of more than 10% of the total body surface area
Severe hepatic failure (Child­Pugh class C) or severe hepatic  
dysfunction: bilirubin concentration ≥ 50 µmol/l (3 mg/dl) + alanine 
aminotransferase concentration ≥ 3 × upper reference value
Traumatic brain injury 
Diabetic ketoacidosis
Hyperosmolar non­ketotic acidosis
Known or suspected hyperlipidaemia
BMI ≤ 17 kg/m2 or severe malnutrition
Pregnancy
The clinician finds that the patient is too deranged (circulation,  
respiration, electrolytes etc.) or that death is imminent
BMI = body mass index; ICU = intensive care unit.
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– Percent of days alive without mechanical ventilation 
at day 90
– Percent of days alive without inotropic/vasopressor 
support at day 90
– Length of stay in ICU and hospital among survivors at 
six months
– 28­day, 90­day and six­month mortality, and survival 
status for all patients six months after randomisation 
of the last patient
– Mental component summary score of SF­36
– Serious adverse reactions (SARs) in the ICU (allergic 
reactions and elevated plasma levels of liver enzymes)
– Cost analyses according to [18, 19].
trial interventions
Intervention group
Primary targets:
– Goal: Delivering 100% of patient­specific require­
ments throughout the entire ICU stay
– Initiation of nutrition ≤ 24 hours of admission (EN + 
PN)
– Measured energy and protein requirements (indirect 
calorimetry, 24­hour urinary urea). 
EN is gradually increased over the first days of admis­
sion. Supplementary PN is given to reach full require­
ments.   
Energy requirement 
Measured using indirect calorimetry (Quark RMR In­
direct Calorimeter from COSMED) as soon as possible  
after inclusion and hereafter every other day.  
Protein requirement
Determined from the preceding day’s 24­hour urinary 
urea using Bistrian’s Equation. A min. of 1.5 g protein/
kg/day is provided, also when 24­hour urinary urea is 
not available/applicable (continuous renal replacement 
FigURE 1
Assessed for eligibility
Randomisation of 200 patients
Excluded if:
– Contraindications to EN/PN
– Need for special diet
– Burn injury
– Liver failure
– Traumatic brain injury
– Diabetic ketoacidosis
– Hyperosmolar non-ketotic acidosis
– Hyperlipidaemia
– BMI < 17 kg/m2
– Pregnancy
– Clinicians discretion/death imminent
Included if:
– Age ≥ 18 years
– Acutely admitted to the ICU
– Expected LOS in ICUY > 3 days
– Mechanically ventilated
– Have CVC
– Written proxy consent obtained
– Able to read and understand Danish
Intervention
– Goal: delivering 100% of patient-speciﬁc requirements 
   throughout entire ICU stay
– Initiation of nutrition ≤ 24 hours of admission (EN + PN)
– Measured energy and protein requirement 
   (indirect calorimetry, 24-hour urinary urea)
Follow-up
Primary outcome measure
Physical function 6 months after randomisation
Secondary outcome measures:
Energy- and protein balance; new organ failure and onset of RRT in the ICU; metabolic control; nosocomial infections; days on RRT, 
MV and on inotropic/vasopressors; LOS ICU & hospital; 28-, 90- and 6-mo. mortality; survival status for all patients; MCS-score of 
SF-36; cost analyses
Control
– Goal: delivering EN as tolerated day 0-7.
   Day 8-discharge EN + PN if necessary
– Initiation of EN < 24 hours of admission
– Calculated energy and protein requirements
Enrollment
Flow diagram for the Early 
Goal­Directed Nutrition in  
ICU Patients Trial. 
BMI = body mass index; CVC = central venous catheter; EN = enteral nutrition; ICU = intensive care unit; LOS = length of stay; MCS = mental com­
ponent summary; MV = mechanical ventilation; PN = parenteral nutrition; CRRT = continuous renal replacement therapy; SF = short form quality 
of life questionnaire.
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therapy (CRRT) or intermittent haemodialysis). Protein 
provision will be reduced below 1.5 g/kg/day at p­urea  
> 20 mmol/l. 
control group
Primary targets
– Goal: Delivering EN as tolerated by patient until day 
7. Supplementary PN may be given by day 8
– Initiation of early EN (≤ 24 hours of admission)
– Calculated energy and protein requirements (25 kcal 
and 1.2 g protein per kg per day as stated in the 
guidelines from The European Society for Clinical 
Nutrition and Metabolism (ESPEN).
EN is gradually increased over the first days of admission 
as tolerated to reach the calculated energy goal. If EN 
fails to reach energy goals by day 7, supplementary PN 
may be initiated at day 8 to reach calculated require­
ments.
Monitoring of included patients 
Glycaemic control is carried out in accordance with best 
evidence, targeting a blood glucose of 6­10 mmol/l. 
 Gastric residual is monitored every 4­6 hours. Flow rate 
of EN will be reduced, and prokinetic therapy may be 
 initiated at the clinicians’ discretion at residuals be­
tween 150 and 500 ml. 
P­triglycerides are measured on admission and 
hereafter on Mondays, Wednesdays and  Fridays. So­
dium and potassium are monitored daily; phosphate, 
magnesium and zink twice a week, and substi tuted as 
needed. Trace elements and vitamins are given daily to 
all patients receiving PN. 
Concomitant treatment
All other interventions and medical treatments are at 
the discretion of the treating clinicians.
Patient withdrawal
Patients may be withdrawn from the trial at any time if 
consent is retracted by the person giving proxy consent, 
next of kin or by the patient. The person withdrawing 
consent will be asked for permission to use the data ac­
quired prior to withdrawal and to obtain data for the pri­
mary outcome measure and mortality. If this is achieved, 
the patient will be included in the final analyses. If the 
person declines, all data will be destroyed, and a new pa­
tient will be randomised to attain the full sample size. Pa­
tients who are withdrawn from the intervention protocol 
will be followed up for the primary endpoint and ana­
lysed as the remaining patients. Intention­to­treat and 
per­protocol analyses will be performed. 
Suspension of nutrition strategy
The nutrition strategy according to randomisation can 
be suspended at any given time by the treating clinician 
or if one or more of the following potential complica­
tions occur: 
– Severe hepatic dysfunction
– SAR or suspected unexpected serious adverse 
reaction (SUSAR)  
– The clinical status of the patient requires unique 
nutritional treatment.
Severe adverse reactions
SARs are recorded as:
– Allergic reactions
– Elevated plasma levels of liver enzymes 
– SUSARs: serious adverse events not described in the 
summaries of product characteristics for the nutrition 
products.
statistics
A total of 200 patients will be included to show a 15% 
relative risk reduction in the primary endpoint (physical 
function) after six months (significance level α = 0.05; 
power β = 80%). The power calculation is based on data 
for physical function (PCS score) and six­month mortality 
extracted from our own published data [1] and the clin­
ical database of the Department of Intensive Care (CIS v. 
3.7.1, Daintel, Copenhagen). Control event rates were 
set to a PCS score of 37.5, standard deviation: ± 10.65 
and a six­month mortality of 40%. The detailed statis­
tical analysis plan is published online and is publically 
available [20].
data handling and record keeping 
Data are handled according to the rules and regulations 
of the Danish Data Protection Agency. All data are regis­
tered from source data and entered into a database by 
FigURE 2
Inclusion in the Early 
Goal­ Directed Nutrition  
in ICU Patients Trial by 4 
April 2016; 203 of 203  
patients included.
0
Pa
ti
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Time
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trained personnel and will be retained at the trial site for 
15 years. Details on data registered in the trial are pub­
lished online and are publically available [20]. 
monitoring
The trial is externally monitored by the good clinical prac­
tice (GCP) Unit, University of Copenhagen, according to 
EU Directive 2001/20, and adheres to the statutory order 
of GCP. Details on the plan for monitoring of the trial are 
published online and are publically available [20]. 
Ethical considerations
The trial adheres to the latest version of the Helsinki 
Declaration from 2010. The trial protocol was approved 
by the Danish Ethics Committee (Case no. 1300461), the 
Danish Medicines Agency (Eudract no. 2011­002547­94) 
and the Danish Data Protection Agency before inclusion 
of the first patient. It is the opinion of the steering com­
mittee that the benefits for the individual patient by 
participating in the trial will outweigh the potential risks.
informed consent
Patients are enrolled after informed consent. As patients 
are unconscious at admission, and the trial requires im­
mediate initiation, inclusion is done after proxy consent 
(two physicians, who are independent of the trial). As 
soon as possible, next of kin and the general practitioner 
of the patient/the Danish Health Authority are asked for 
consent. Eventually, informed consent from the patient 
is obtained when/if the patient regains consciousness.  
duration
The last patient was included on 4 April 2016, one week 
after the submission of this manuscript (Figure 2). We 
expect completion of six­month follow­up of the last 
randomised patient in October 2016.
timeline
– 2012­2013: Applications for funding. Submission to 
Ethics Committee, Danish Medicines Agency and the 
Danish Data Protection Agency. Development of CRFs 
and data management tools and plan for monitoring
– 2013­2016: Inclusion of patients
– 2016­2017: Data analyses, writing of manuscript and 
publications. 
Publication plan
Upon completion of the trial the results will be sub­
mitted to one of the major international peer­viewed 
journals regardless of the nature of the results.
Finances
The EAT­ICU trial is funded by Copenhagen University 
Hospital, Rigshospitalet and Fresenius Kabi A/S and sup­
ported by The European Society for Clinical Nutrition 
and Metabolism (ESPEN). None of the funding sources 
will have any influence on trial design, trial execution, 
data handling, analyses or publication. 
Trial registration: Clinicaltrials.gov identifier no. 
NCT01372176.
discUssiOn
Optimal nutrition for the ICU patient remains unsettled. 
In the EAT­ICU trial we test a strategy of an optimised 
protein­energy nutrition based on measured require­
ments with the aim of improving short­term clinical out­
come as well as long­term physical function.
The strength of the study is the multimodal nutri­
tion therapy testing the conjunction of adequate provi­
sion of both energy and protein given based on meas­
ured requirements. Such a nutritional therapy has not 
been tested in any of the previous randomised trials 
published in the recent years. The obvious limitations  
of the trial are the single­centre design, the relatively 
limited sample size and the fact that clinicians, patients 
and investigators are not blinded to the intervention. 
Thus, the results of the EAT­ICU should be interpreted 
with some caution.
trial status 
The trial was initiated on 24 June 2013 and inclusion of 
patients was concluded on 4 April 2016. A total of 586 
patients have been screened and 203 patients are in­
cluded in total (Figure 2). 
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